Cassava Sciences, Inc. Stock price

Equities

SAVA

US14817C1071

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
20.29 USD -0.64% Intraday chart for Cassava Sciences, Inc. -4.20% -9.86%
Sales 2024 * - Sales 2025 * 300M Capitalization 877M
Net income 2024 * -92M Net income 2025 * 120M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 2.92 x
P/E ratio 2024 *
-10.1 x
P/E ratio 2025 *
12.1 x
Employees 29
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.82%
More Fundamentals * Assessed data
Dynamic Chart
Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam MT
Cassava Sciences, Inc. Announces Completion of an Interim Safety Review of Oral Simufilam On-Going Phase 3 Trials CI
Cassava Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Cassava Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Cassava Sciences, Inc. Reports Results of Two-Year Clinical Safety Study of Simufilam, an Investigational Oral Drug for the Proposed Treatment of Alzheimer?s Disease Dementia CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2000 Index CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 3000 Index CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2500 Index CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell Small Cap Completeness Index CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell Small Cap Comp Growth Index CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 3000 Growth Index CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2500 Growth Index CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 3000E Index CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 3000E Growth Index CI
Cassava Sciences, Inc.(NasdaqCM:SAVA.W) dropped from Russell 2000 Dynamic Index CI
More news
1 day-0.64%
1 week-4.20%
Current month-11.71%
1 month-11.51%
3 months-10.93%
6 months+20.34%
Current year-9.86%
More quotes
1 week
19.51
Extreme 19.5066
20.90
1 month
18.18
Extreme 18.18
23.28
Current year
18.18
Extreme 18.18
27.37
1 year
12.32
Extreme 12.3202
32.10
3 years
12.32
Extreme 12.3202
146.16
5 years
1.00
Extreme 1
146.16
10 years
0.76
Extreme 0.76
146.16
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 98-04-30
Director of Finance/CFO 55 18-09-30
Chief Tech/Sci/R&D Officer - 21-01-03
Members of the board TitleAgeSince
Chief Executive Officer 64 98-04-30
Director/Board Member 86 03-02-28
Director/Board Member 76 07-12-06
More insiders
Date Price Change Volume
24-03-28 20.29 -0.64% 470,343
24-03-27 20.42 +3.60% 377,252
24-03-26 19.71 +0.05% 380,221
24-03-25 19.7 -0.56% 562,453
24-03-22 19.81 -6.47% 639,020

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Cassava Sciences, Inc. is a biotechnology company focused on Alzheimer's disease. The Company's science is based on stabilizing, but not removing, a critical protein in the brain. The Company is focused on its product discovery and development efforts on disorders of the nervous system. Its lead therapeutic drug candidate, simufilam, is under clinical evaluation for the proposed treatment of Alzheimer's disease dementia in Phase 3 clinical studies. The Company has two biopharmaceutical assets under development. Its lead therapeutic product candidate, called simufilam, is an oral treatment for Alzheimer's disease dementia. Its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer's disease from a small sample of blood. Simufilam targets an altered form of a protein called filamin A in the Alzheimer's brain. It owns rights to its drug and diagnostic assets and related technologies, without royalty obligations to any third party.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
20.29 USD
Average target price
124 USD
Spread / Average Target
+511.14%
Consensus
  1. Stock
  2. Equities
  3. Stock Cassava Sciences, Inc. - Nasdaq